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Abstract
Background: Bilirubin has been reported to be associated with respiratory diseases due to its antioxidant action.
We aimed to evaluate the relationship between serum bilirubin concentration and annual lung function decline in
the Korean general population.
Methods: The study included 7986 subjects aged 40–69 years from the Ansung-Ansan cohort database I (2001–
2002)–III (2005–2006). We analyzed the relationships between serum bilirubin level and forced expiratory volume in
1 s (FEV1), forced vital capacity (FVC), FEV1/FVC, and mean forced expiratory flow between 25 and 75% of FVC
(FEF25–75%) at baseline, as well as the annual average changes in these lung parameters.
Results: The FEV1, FVC, and FEF25–75% were significantly associated with serum bilirubin levels after adjustment for
age, sex, body mass index (BMI), and smoking status (all P < 0.001). When stratified according to smoking status,
these relationships were significant in never-smokers. Additionally, serum bilirubin level was negatively associated
with the annual decline in FEV1 and FVC, and positively associated with the annual decline in FEV1/FVC after adjustment
for age, sex, BMI, baseline lung function, and smoking status (all P < 0.001).
Conclusions: We found significant associations of serum bilirubin levels with FEV1, FVC, and FEF25–75% in the general
population, especially in never-smokers. Moreover, serum bilirubin levels were related with the annual decline in FEV1,
FVC, and FEV1/FVC ratio.
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Background
Serum total bilirubin is routinely measured to identify
hepatobiliary and hemolytic diseases. Bilirubin is an
end-product of heme degradation that has raised consid-
erable interest over the last decade [1]. The benefits of
elevated serum bilirubin are supported by animal and in
vitro experiments showing antioxidant and anti-inflam-
matory properties [2]. In clinical studies, increased
serum bilirubin has been associated with decreased risk
for myocardial infarction, coronary artery disease, and
stroke [3, 4] as well as lower incidence of lung cancer,
chronic obstructive lung disease, and lung cancer mor-
tality [5, 6]. It has been suggested that bilirubin might
have protective effects in tissues exposed to the outer
environment, such as the lungs, possibly by counteract-
ing subclinical inflammation [3–6].
Only few previous studies have reported the relation-
ship between serum bilirubin level and lung function pa-
rameters [7, 8]. In the study by Curjuric et al., higher
bilirubin levels were associated with higher forced ex-
piratory volume in 1 s (FEV1)/forced volume capacity
(FVC) ratio and forced expiratory flow at 25–75%
(FEF25–75%) in the Swiss general population [7]. In the
study by Apperley et al., serum bilirubin was positively
related to FEV1 and negatively related to the annual de-
cline in FEV1 in subjects with chronic obstructive pul-
monary disease (COPD) with mild to moderate airflow
limitation [8]. However, the relationships between bili-
rubin levels and decline in lung function parameters in
the healthy general population have not been reported
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before. We aimed to evaluate the relationship between
serum bilirubin concentration and annual lung function
decline in the Korean general population.
Methods
Study population
The Ansung-Ansan cohort study is an ongoing prospect-
ive study that was started in 2001 with support from the
National Genome Research Institute (Korea Centers for
Disease Control and Prevention, Cheongju, Korea). The
study is a part of the Korean Genome and Epidemiology
Study, a large community-based epidemiologic survey to
investigate chronic disease in Koreans. Detailed infor-
mation on the study design and procedures has been
published previously [9, 10]. Each study comprised a
population-based sample of male and female Koreans
aged 40–69 y and from the same ethnic background,
but cohort members were enrolled at the following 2
different sites: Ansan, which is an urban community
with a population of 555,000, and Ansung, which is a
rural community including 133,000 residents, on the
basis of the 2000 census. To enroll members for each
cohort, the most efficient method was used on the basis
of knowledge about characteristics of each community.
For enrollment at the Ansan site, 10,957 eligible subjects
were identified by telephone contact on the basis of a
2-stage cluster-sampling method with the information of a
governing district called Dong and demographic charac-
teristics. Similarly, Ansung members were recruited from
5 of 11 governing districts called Myon by using a
cluster-sampling method, and as a result, 7192 eligible
subjects were identified by mail or telephone contact and
a door-to-door visit. For the baseline health examination
from 18 June 2001 to 29 January 2003, 5020 participants
(2523 men and 2497 women) from Ansan and 5018 (2239
men and 2779 women) from Ansung visited the Korea
University Ansan Hospital and the Ajou University
Medical Center, respectively. Cohort members were
followed up biennially with a scheduled site visit for simi-
lar interviews and health examinations (I: 2001–2002,
II: 2003–2004, III: 2005–2006).
In these subjects, initial data were obtained from 9785
subjects aged 40–69 years who participated in Ansung-
Ansan cohort I (2001–2002) and had valid lung func-
tion measurements without previous history of asthma,
COPD, or hepatobiliary disease. Follow-up examina-
tions are conducted biennially. Data from a baseline
survey and two subsequent biennial surveys (I–III:
2001–2006) were analyzed in our study. Of the 9785
subjects in the study, 42 participants with total bilirubin
concentrations > 1.75 mg/dL for women and > 2.34 mg/dL
for men were excluded from the analysis. Finally, 7986
who underwent pulmonary function testing two times or
more during I–III were used as the study population in
this study (Fig. 1). The median follow-up duration was
3.6 years.
Bilirubin measurement
At baseline, venous blood samples were collected from
eligible participants who originally consented, on the
same day of lung function tests. Serum bilirubin was
quantified by biochemical assays, performed by a central
laboratory (Seoul Clinical Laboratories, Seoul, Korea)
[11]. As described above, total bilirubin concentrations
> 1.75 mg/dL for women and > 2.34 mg/dL for men were
excluded from analysis. These limits represent concen-
trations 1 standard deviation (SD) above the mean
serum total bilirubin associated with the most common
variant of Gilbert syndrome, a benign hereditary cause
of indirect hyperbilirubinemia [5].
Lung function measurement
Lung function was measured by spirometry (VMAX2130,
SensorMedics Corporation, Yorba, CA, USA) at every visit
(at baseline, and at the first and second follow-up visits).
Lung function decline was calculated as the difference
in FEV1 measurements between the first and last meas-
urement in each time interval divided by the number of
years between measurements.
Definitions
We considered ‘never-smokers’ those individuals who de-
clared that they never smoked before the study, ‘former
smokers’ those smokers who declared that they had
smoked before and stopped before the study, and ‘con-
tinuous smokers’ those smokers who declared active
smoking in the study period.
Statistical analysis
We analyzed the relationships between bilirubin and
FEV1, FVC, FEV1/FVC, and FEF25–75% at baseline, and
the annual average decline of these lung parameters.
Participants were divided into quintiles of bilirubin
Fig. 1 Flow chart of participant selection
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concentration, and baseline characteristics were compared
using analysis of variance or Cochran-Mantel-Haenszel’s
test for trend. We performed the analysis using linear re-
gression and bilirubin as a continuous variable rather than
in quintiles. Linear regression with adjustment for age,
sex, body mass index (BMI), and smoking status was used
to examine the relationship between bilirubin and lung
function parameters such as FEV1, FVC, FEV1/FVC ratio,
and FEF25–75%. The linear mixed model was used to
evaluate the relationship between bilirubin and repea-
ted-measured FEV1, FVC, FEV1/FVC, and FEF25–75%. All
analyses were performed using R version 3.1.3 (http://




The demographics and clinical characteristics of the
7986 participants, stratified by quintiles of bilirubin con-
centration, are presented in Table 1. Age was negatively
related to serum bilirubin concentration (P < 0.001). The
proportion of male gender was positively related to serum
bilirubin (P < 0.001). The proportion of continuous
smokers and former smokers was increased while that of
never-smokers was decreased toward higher quintiles of
bilirubin concentration (P < 0.001). Lung function pa-
rameters of FEV1, FVC, FEV1/FVC, and FEF25–75% were
positively related to serum bilirubin level (all P < 0.001)
(Table 1).
Associations of bilirubin with lung function parameters
Table 2 shows the relationship between serum bilirubin
and lung function according to smoking status, adjusted
for covariates. When stratified by smoking status and ad-
justed for age, sex, and BMI, a positive relationship between
bilirubin quintiles and FEV1 was present in continuous
smokers (P = 0.048) and never-smokers (P < 0.001). When
bilirubin was analyzed as a continuous variable, the positive
relationship between bilirubin concentration and FEV1 was
present only in never-smokers (P < 0.001). Lung function of
FVC was positively related with bilirubin quintiles (P =
0.018) and bilirubin level as continuous variable (P = 0.012)
only in never-smokers. Positive relationship was ob-
served between bilirubin quintile and FEV1/FVC ratio
in never-smokers (P = 0.026). However, when bilirubin
was analyzed as a continuous variable, the effect of biliru-
bin on FEV1/FVC ratio was not statistically significant.
There was a significant positive relationship between bili-
rubin and FEF25–75% in never-smokers (P < 0.001 for quin-
tile analysis, P = 0.001 for continuous variable analysis).
The results of multivariate regression analysis for the
effect of serum bilirubin levels on repeated measures of
lung function are described in Table 3. The FEV1 (esti-
mated mean = 0.12, P < 0.001), FVC (estimated mean =
0.14, P < 0.001), and FEF25–75% (estimated mean = 0.15,
P < 0.001) were significantly associated with baseline bili-
rubin levels after adjustment for age, sex, BMI, and
smoking status (Table 3). FEV1/FVC ratio tended to be
related with baseline bilirubin level (estimated mean =
0.51, P = 0.0595).
Table 1 Baseline characteristics of the study participants by quintiles of bilirubin concentration
Parameters Quintile I Quintile 2 Quintile 3 Quintile 4 Quintile 5 P for
Trend(n = 1534) (n = 1618) (n = 1611) (n = 1600) (n = 1623)
Bilirubin, umol/L 0.29 ± 0.05 0.42 ± 0.03 0.53 ± 0.04 0.68 ± 0.05 1.04 ± 0.26 < 0.001
Age, y 53.9 ± 9.0 53.1 ± 8.8 51.7 ± 8.6 51.1 ± 8.4 49.9 ± 8.4 < 0.001
Sex, male 401(26.14) 616(38.07) 750(46.55) 959(59.94) 1136(69.99) < 0.001
BMI 24.5 ± 3.2 24.7 ± 3.2 24.7 ± 3.2 24.8 ± 2.9 24.6 ± 2.9 0.539
Smoking (baseline) < 0.001
Continuous smoker 311(20.27) 400(24.72) 409(25.39) 454(28.38) 422(26.00)
Former smoker 117(7.63) 169(10.44) 241(14.96) 307(19.19) 452(27.85)
Never smoker 1106(72.10) 1049(64.83) 961(59.65) 839(52.44) 749(46.15)
Pack-Y smoking 24.9 ± 18.6 24.6 ± 17.5 23.4 ± 15.8 24.5 ± 17.3 20.1 ± 15.8 < 0.001
Lung function
FEV1, L 2.62 ± 0.61 2.78 ± 0.66 2.93 ± 0.67 3.06 ± 0.69 3.20 ± 0.68 < 0.001
FVC, L 3.30 ± 0.78 3.51 ± 0.85 3.70 ± 0.97 3.84 ± 0.87 4.00 ± 0.83 < 0.001
FEV1/FVC, % 79.9 ± 7.6 79.7 ± 7.6 79.8 ± 7.5 80.2 ± 7.3 80.3 ± 7.3 0.044
FEF25–75%, L/s 2.75 ± 1.02 2.87 ± 1.03 3.05 ± 1.10 3.20 ± 1.16 3.46 ± 4.17 < 0.001
Notes: Data are presented as the number (%) or the mean ± standard deviation
Abbreviations: BMI body mass index, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, FEF25–75% forced expiratory flow between 25 and 75% of
vital capacity
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Bilirubin and lung function decline
Figures 2, 3, and 4 show the relationship between biliru-
bin and the decline of lung function parameters. Higher
bilirubin concentration was significantly related to re-
duced rate of annual decline in FEV1 (Fig. 2a) and FVC
(Fig. 3a) (all P < 0.001). After adjustment for age, sex, BMI,
baseline lung function, and smoking status, this inverse
relationship persisted (all P < 0.001) (Figs. 2b and 3b).
The annual change in FEV1/FVC ratio was positively
associated with bilirubin concentration in univariate and
multivariate adjusted analysis (all P < 0.001) (Fig. 4a, b).
Discussion
In this population-based study, serum bilirubin was posi-
tively related with FEV1, FVC, and FEF25–75%. When
stratified according to smoking status, these relationships
were prominent in never-smokers. Furthermore, bilirubin
concentration was inversely related to the rate of decline
Table 2 Relationship between serum bilirubin and lung function according to smoking status
Lung function
parameters
Bilirubin (Quintiles) Bilirubin (Continuous)
Quintile I Quintile 2 Quintile 3 Quintile 4 Quintile 5 P for Trend ß ± SE P-value
FEV1, L
Continuous smoker 3.02 ± 0.62 3.17 ± 0.66 3.3 ± 0.62 3.44 ± 0.57 3.44 ± 0.6 0.048 0.09 ± 0.05 0.061
Former smoker 3.04 ± 0.69 3.21 ± 0.71 3.33 ± 0.64 3.43 ± 0.62 3.48 ± 0.61 0.193 0.02 ± 0.05 0.619
Never smoker 2.5 ± 0.51 2.57 ± 0.53 2.67 ± 0.55 2.77 ± 0.59 2.95 ± 0.64 < 0.001 0.10 ± 0.03 < 0.001
FVC, L
Continuous smoker 3.95 ± 0.83 4.19 ± 0.79 4.3 ± 0.72 4.37 ± 0.68 4.38 ± 0.67 0.262 0.04 ± 0.06 0.441
Former smoker 3.94 ± 0.75 4.08 ± 0.79 4.21 ± 0.69 4.37 ± 0.69 4.32 ± 0.64 0.454 −0.02 ± 0.06 0.772
Never smoker 3.08 ± 0.6 3.16 ± 0.64 3.31 ± 0.98 3.39 ± 0.73 3.61 ± 0.79 0.018 0.10 ± 0.04 0.012
FEV1/FVC, %
Continuous smoker 77.11 ± 7.71 76.42 ± 8.51 77.39 ± 7.63 78.54 ± 7.97 79.35 ± 7.48 0.205 1.02 ± 0.64 0.109
Former smoker 76.98 ± 9.09 77.85 ± 8.49 78.26 ± 8.01 78.88 ± 6.54 79.6 ± 7.27 0.516 0.52 ± 0.65 0.423
Never smoker 81.36 ± 6.68 81.62 ± 6.39 81.53 ± 6.37 81.99 ± 6.28 81.96 ± 6.16 0.027 0.76 ± 0.41 0.061
FEF25–75%, L/s
Continuous smoker 2.88 ± 1.15 2.98 ± 1.23 3.16 ± 1.21 3.43 ± 1.34 3.97 ± 8.54 0.063 0.53 ± 0.39 0.176
Former smoker 2.83 ± 1.14 3.05 ± 1.18 3.26 ± 1.3 3.4 ± 1.19 3.53 ± 1.27 0.267 0.06 ± 0.10 0.534
Never smoker 2.77 ± 0.97 2.85 ± 0.91 2.97 ± 0.95 3.1 ± 1.02 3.28 ± 1.06 < 0.001 0.18 ± 0.06 0.001
Notes: Data are presented as the mean ± standard deviation. Bilirubin was analyzed across quintiles and as a continuous variable
P-value for linear trend analysis adjusted for age, sex, and body mass index
Abbreviations: SE standard error, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, FEF25–75% forced expiratory flow between 25 and 75% of vital capacity




Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
FEV1, L
Estimated mean (SE) 0.12(0.02) ref 0.03(0.02) 0.06(0.02) 0.07(0.02) 0.11(0.02)
P-value < 0.001 0.154 0.002 < 0.001 < 0.001
FVC, L
Estimated mean (SE) 0.14(0.02) ref 0.05(0.02) 0.10(0.02) 0.09(0.02) 0.13(0.02)
P-value < 0.001 0.018 < 0.001 < 0.001 < 0.001
FEV1/FVC, %
Estimated mean (SE) 0.51(0.27) ref −0.39(0.25) −0.47(0.25) 0.22(0.25) 0.26(0.25)
P-value 0.059 0.113 0.055 0.371 0.307
FEF25–75%, L/s
Estimated mean (SE) 0.15(0.04) ref 0.01(0.05) 0.03(0.05) 0.11(0.05) 0.20(0.05)
P-value < 0.001 0.857 0.575 0.022 < 0.001
Notes: Data were adjusted for age, sex, body mass index, and smoking status (current smoker, former smoker, and never-smoker)
Abbreviations: SE standard error, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, FEF25–75% forced expiratory flow between 25 and 75% of vital capacity
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in FEV1 and FVC (mL/year). The annual decline in FEV1/
FVC ratio was positively associated with bilirubin con-
centration. This is the first longitudinal study investi-
gating the relationships between bilirubin levels and the
changes of lung function parameters based on a general
population-based cohort.
The beneficial effects of serum bilirubin on respiratory
outcomes have been reported in several studies [5, 6, 12].
In a previous study by Temme et al., high serum bilirubin
was associated with lower cancer mortality, including that
of lung cancer [6]. In a study by Horsfall et al., relatively
higher levels of bilirubin were associated with a lower risk
of respiratory diseases such as lung cancer and COPD,
and all-cause mortality among patients with normal-range
bilirubin levels in primary care practices of United King-
dom [5]. It was the first large epidemiologic study to find
that bilirubin concentration is negatively associated with
COPD incidence. In a report by Brown et al., higher biliru-
bin was associated with a significantly lower hazard for
acute exacerbation of COPD [12]. These results of previ-
ous studies suggest that bilirubin might have protective ef-
fects in lung tissues, possibly by counteracting subclinical
inflammation. The results of our study are in line with
previous results in that they showed the lung protective
effect of bilirubin.
Only few studies about the relationship between biliru-
bin levels and lung function have been reported [7, 8].
Curjuric et al. showed that high bilirubin levels were
significantly associated with higher FEV1/FVC and
FEF25–75% in the Swiss general population sample [7].
In that cross-sectional study, decreased serum bilirubin
levels were associated with increased risk of COPD [7].
It was the only study that investigated the relationships
between serum bilirubin and lung function in a healthy
Fig. 2 Average annual decline of FEV1 relative to the natural logarithm of serum bilirubin. Notes: Bilirubin is expressed in mg/dL in parentheses.
a Univariate relationship (linear regression coefficienct = − 9.93) and b relationship adjusted for age, sex, BMI, FEV1 at baseline, and smoking
status (current smoker, former smoker, and never-smoker)(linear regression coefficienct = − 13.09). Abbreviations: BMI, body mass index; FEV1,
forced expiratory volume in 1 s
Fig. 3 Average annual decline of FVC relative to the natural logarithm of serum bilirubin. Notes: Bilirubin is expressed in mg/dL in parentheses.
a Univariate relationship (linear regression coefficienct =− 26.04) and b relationship adjusted for age, sex, BMI, FVC at baseline, and smoking status (current
smoker, former smoker, and never smoker)(linear regression coefficienct =− 24.19). Abbreviations: BMI, body mass index; FVC, forced vital capacity
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general population. For FEF25–75%, the results of that
study were consistent with ours. The significant associ-
ations with FEF25–75% might be related to the inverse
relationship of bilirubin concentrations with small air-
way obstruction. However, both FEV1 and FVC were
positively related to bilirubin concentration in our
study, inconsistent with the results of Curjuric et al. in
which bilirubin concentration was not significantly re-
lated to FEV1 or FVC. The differences in proportion of
sex, distribution of smoking status, covariates adjusted
may have resulted in different outcomes. In another
study, Apperley et al. reported that serum bilirubin was
positively related to FEV1 and negatively related to the
annual decline in FEV1 in patients with mild to moder-
ate COPD [8]. This was the only study that evaluated
the relationships between serum bilirubin levels and
the decline of FEV1 in patients with COPD [8]. We ex-
tended these results by demonstrating that serum bili-
rubin levels relate to FEV1 and FEV1 decline in a large
community-based cohort of general population. Further-
more, we showed the relationships between serum biliru-
bin levels and other lung function parameters such as
FVC, FEV1/FVC ratio, and FEF25–75%.
One study reported the relationships between serum
inflammatory biomarkers, including total bilirubin, and
COPD in never-smokers in the Korean population [13].
In that study, serum bilirubin concentration was not
significantly associated with the presence of COPD in
never-smokers [13]. However, the limitation of the study
is that the sample size was small, and the relationship of
bilirubin level with lung function was not assessed.
The possible related biological mechanisms of the role
of bilirubin on lung function in COPD patients have
been reported [14–17]. When heme is degraded to bili-
verdin by heme oxygenase, the production of bilirubin
begins [14]. Biliverdin is subsequently reduced to bilirubin
by biliverdin reductase [14]. Heme oxygenase-1 (HO-1),
the inducible isoform of heme oxygenase expressed in
type 2 pneumocytes and alveolar macrophages in the lung,
has been reported to be up-regulated by oxidative stress
and hypoxia [15, 16]. Genomic studies have found that the
relative gene expression of heme oxygenase and biliverdin
reductase is high in lung tissue [17]. The HO-1 gene con-
tains a variable number of GT nucleic acid repeats in its
flanking region, and individuals with fewer GT repeats
have higher serum bilirubin concentrations and a lower
risk of COPD [18, 19].
In COPD, oxidative stress is affected by both endogen-
ously produced oxidants and exogenous sources such as
smoking. An animal study using animal model supported
a protective effect of increased bilirubin against respira-
tory injury by environmental stressors [20]. In the study
by Sedlak et al., bilirubin had a greater affinity in pre-
venting oxidation of lipids, and inhibition of bilirubin
synthesis resulted in significant increases in lipid perox-
idation products [20].
In human lungs, it is reported that oxidant-antioxidant
imbalance is associated with airways obstruction, and
Fig. 4 Average annual changes in FEV1/FVC ratio relative to the natural logarithm of serum bilirubin. Notes: Bilirubin is expressed in mg/dL in
parentheses. a Univariate relationship (linear regression coefficienct = 2.64) and b relationship adjusted for age, sex, BMI, FEV1/FVC ratio at baseline, and
smoking status (current smoker, former smoker, and never-smoker)(linear regression coefficienct = 1.69). Abbreviations: BMI, body mass index;
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity
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altered oxidant-antioxidant balance in patients with
COPD increases in parallel with the severity of the disease
[21]. Repine et al. reported that lipid peroxidation causes
damage to multiple cell membrane components and im-
pairs cell structure and permeability [22]. Patients with
COPD have higher levels of lipid peroxidation products in
sputum [23], and serum levels of these products are
higher in patients with severe airflow limitation compared
with those with moderate limitation [24]. Based on these
results, we suggest that bilirubin might protect the lungs
by inhibiting lipid peroxidation [21–24].
To our knowledge, this is the first longitudinal study
that analyzed the relationships between bilirubin levels
and changes in lung function parameters in the healthy
general population. The study was conducted in a pro-
spective, large cohort using various spirometric measures.
However, the study also has several limitations. First, the
follow-up period was relatively short, yet the Ansung-
Ansan cohort study is still ongoing. We expect to be able
to analyze the data further with longer follow-up. Second,
we used pre-bronchodilator spirometric values instead of
post-bronchodilator values. Third, serum bilirubin concen-
tration was only measured at baseline and it is unsure if
bilirubin level was stable during the follow-up period.
Therefore, the relationships between the changes of biliru-
bin concentration and lung function decline could not be
analyzed. Lastly, the information on alcohol consumption,
previous drug intake, or diet which can affect bilirubin level
was not fully investigated in this cohort study.
Conclusions
We found significant positive associations of serum biliru-
bin levels with FEV1, FVC, and FEF25–75% in the general
population, especially in never-smokers after adjustment
of age, sex, BMI, and smoking status. Furthermore, serum
bilirubin concentration was also significantly related to
the annual changes in FEV1, FVC, and FEV1/FVC ratio.
Further research is needed to investigate causal associa-
tions between bilirubin levels and lung function.
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